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Oral Presentations S241previously reported aHSCT patients take a median of 17 (range 3-
49) medications daily at Mayo Clinic. This study aimed to determine
if medication burden correlates with quality of life (QoL) at 1 year
following HSCT.
Methods: As part of an ongoing, IRB approved QoL study we ex-
amined the cross-sectional relationship between medication burden
and QoL among all adult aHSCT patients with adequate documen-
tation and follow-up between 7/1/09 and 9/30/10. Medication bur-
den was assessed by number of scheduled medications, maximum
possible doses and maximum possible pills per day reconciled by
a pharmacist pre-HSCT and 1 year post-HSCT. QoL was assessed
by the Functional Assessment of Cancer Therapy (FACT)-General
(version 4) during pre-HSCT evaluation and FACT-BMT 1 year
post-HSCT.
Results: During the study period, 57 patients received an aHSCT
and enrolled in the QoL study; 43 patients were included. Patients
were excluded for death before 1 year (n 5 13), incomplete medi-
cation record (n 5 1), missing post-HSCT QoL data (n 5 2). Me-
dian patient age was 55 years (range of 24-71); 50% of patients
were male and most patients had an ECOG performance score of
0 or 1 (n 5 1 ECOG of 2). Pre-HSCT total scheduled pills per
day negatively correlated with social well being. Pre-HSCT,
a higher number of maximum possible pills per day (scheduled
and prn) was associated with worse pre-transplant QoL across do-
mains of physical, social, functional, and overall well-being. The as-
sociations with physical, social, and total well-being remained
significant after adjustment for age, gender, and ECOG perfor-
mance score. A higher pre-HSCT maximum possible pills per
day correlates with worse physical and overall well being 1-year
post-HSCT. Post-transplant a higher number of maximum possi-
ble pills per day negatively correlated with physical, functional,
and overall well-being 1 year post-transplant, even after covariate
adjustment.
Conclusion: These data offer preliminary evidence that maximum
daily pill count (scheduled and prn) might be a significant predictor
of QoL among HSCT recipients. Better understanding of which as-
pects of medication burden (e.g., pill count, medication type) affect
domains of QoLmay help identify possible medication management
strategies to improve QoL.102
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Background:Cyclophosphamide (Cy) has been shown to be an ef-
fective regimen for HSC mobilization in NHL patients undergoingTable.
Cy2 (n 5 28) Cy3 (n 5 31) Cy4 (n 5 28
Collect $2x106 in #2 days 39% 87% 82%
Collect$5x106 in #2 days 14% 42% 46%
Collect$5x106 in all days 18% 45% 64%
Collect$2x106 in all days 89% 100% 100%
Median # of collections 3 2 2
% Patients hospitalized for FN 0% 16% 32%
Hospitalization Days (median) 0 3 4
Days of G-CSF (median) 11.5 12.5 10.5
% Pts receiving plerixafor 32% 42% 4%
Relative Mobilization Cost
(normalized to Cy4)
1.47 1.37 1.00autologous stem cell transplantation (ASCT). However, the opti-
mal dose to be used, which maximizes HSC collection yields while
minimizing febrile neutropenia and other toxicities, remains con-
troversial. Three successive cohorts of NHL patients who received
G-CSF and Cy at doses of either 4g/m2 (Cy4), 2g/m2 (Cy2) or 3g/
m2 (Cy3) were compared.
Methods: 31 pts undergoing Cy3 mobilization between October
2009 and August 2011 were retrospectively analyzed and com-
pared to our historical Cy2 (n 5 28) and Cy4 (n 5 28) data.
Minimal and optimal yield was defined as collection of $2 x
106 and $5 x 106 CD34+ cells/kg, respectively. Apheresis was
initiated utilizing WBC and CD34+ cell count to guide start of
collection and preemptive plerixafor use, whereas in historical
Cy4 and Cy2 cohorts, plerixafor was only used following mobi-
lization failure.
Results:Minimal cell dose required for ASCT was achieved in the
majority of patients in all groups (89%, 100% and 100% of Cy2, 3,
and 4 pts, respectively). However, the collection efficiency clearly
favored Cy3 and Cy4, with the proportion of patients collecting
$2 x 106 CD34+ cells/kg in 2 days being 87% and 82%, respec-
tively vs. 39% for Cy2 (p\0.001). In contrast, toxicity, as measured
by % febrile neutropenia and median hospitalization days, favored
Cy2 (0%, 0d) compared with Cy4 (32%, 4d, p 5 0.002), with Cy3
falling intermediate between these groups (16%, 3d). Requirement
for Plerixafor was significantly higher for both Cy2 (32%) and Cy3
(42%), compared with Cy4 (4%, p 5 0.003). Relative cost clearly
favored Cy4, when accounting for the combined costs of Cy, G-
CSF, plerixafor, hospitalization, and apheresis, with Cy3 and Cy2
costing approximately 37% and 47% more, respectively, per pa-
tient mobilization.
Conclusions: Although Cy2, 3, and 4 are all effective mobilizing
regimens, collection efficiency, toxicity, and cost vary greatly. Both
Cy3 and Cy4 improve collection efficiency, at the expense of in-
creased hospitalization, particularly with Cy4. Cy4 appears to max-
imize collection efficiency while minimizing plerixafor use and
overall cost. Further improvements in supportive care strategies to
reduce the incidence of febrile neutropenia and associated hospital-
ization are clearly needed.103
ONCE DAILY DOSE (ODD) LORAZEPAM (LO) FOR SEIZURE PROPHYLAXIS
IN CONJUNCTIONWITH ONCE DAILY DOSE BUSULFAN (BU) FOR PEDIAT-
RIC PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING (RIC)
FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT)
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BU is an alkylating agent used as part of conditioning for
HSCT. It is known to cause seizures in the 3rd and 4th day of) P-value
Pairwise Comparison (significant if p-value<0.017
based on Bonferroni adjustment)
Cy2 vs Cy3 Cy2 vs Cy4 Cy3 vs Cy4
<0.001 <0.001 0.001 0.597
0.022 0.019 0.009 0.729
0.002 0.025 <0.001 0.141
n.s N/A N/A N/A
<0.001 <0.001 0.011 0.830
0.002 0.062 0.002 0.127
0.004 0.033 0.002 0.113
n.s N/A N/A N/A
0.003 0.437 0.005 <0.001
